These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28251276)

  • 1. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection.
    Plessis L; Gómez A; García N; Cereza G; Figueras A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):751-758. PubMed ID: 28251276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China.
    Niu R; Xiang Y; Wu T; Zhang Z; Chen Y; Feng B
    Expert Opin Drug Saf; 2019 Jan; 18(1):51-58. PubMed ID: 30574811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade.
    Tsuchiya M; Obara T; Miyazaki M; Noda A; Takamura C; Mano N
    Int J Clin Pharm; 2020 Apr; 42(2):728-736. PubMed ID: 32020439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
    Tandon VR; Mahajan V; Khajuria V; Gillani Z
    Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.
    Pacurariu AC; Straus SM; Trifirò G; Schuemie MJ; Gini R; Herings R; Mazzaglia G; Picelli G; Scotti L; Pedersen L; Arlett P; van der Lei J; Sturkenboom MC; Coloma PM
    Drug Saf; 2015 Dec; 38(12):1201-10. PubMed ID: 26370104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
    Scholl JH; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study.
    Zhang X; Niu R; Feng B; Guo J; Liu Y; Liu X
    Expert Opin Drug Saf; 2019 Jan; 18(1):59-68. PubMed ID: 29883236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015.
    van Hunsel F; de Waal S; Härmark L
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):977-983. PubMed ID: 28524293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?
    Kheloufi F; Default A; Rouby F; Laugier-Castellan D; Boyer M; Rodrigues B; Ponte-Astoul J; Jean-Pastor MJ; Blin O; Micallef J
    Eur J Clin Pharmacol; 2017 Aug; 73(8):1009-1018. PubMed ID: 28391408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
    Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
    Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014.
    Awodele O; Ibrahim A; Orhii P
    Int J Risk Saf Med; 2016 Mar; 28(1):13-23. PubMed ID: 27176753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports.
    Oosterhuis I; Rolfes L; Ekhart C; Muller-Hansma A; Härmark L
    Expert Opin Drug Saf; 2018 Feb; 17(2):111-115. PubMed ID: 29157026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.